Battalgazi

Researchers are investigating the effects of Morus nigra (black mulberry) mouthwash as an addition to standard non-surgical treatment for generalized gingivitis. This study aims to evaluate clinical, microbiological, and biochemical changes in patients receiving scaling and root planing (SRP) alone versus those using SRP plus Morus nigra mouthwash. The trial includes 30 patients diagnosed with generalized gingivitis to explore the anti-inflammatory and antioxidant benefits of this herbal mouthwash. Participants will be divided into two groups. One group will receive only SRP, which mechanically removes dental plaque and calculus from tooth surfaces. The other group will receive SRP plus use Morus nigra mouthwash twice daily for 14 days. Clinical parameters such as the Gingival Index and Plaque Index will be recorded. Biochemical analysis of inflammatory markers in gingival fluid and microbiological analysis of subgingival bacteria will be conducted using ELISA and Real-time PCR respectively. During the study, patients will be assessed at baseline, 1 month, and 3 months. Researchers will measure changes in the Gingival Index to evaluate gum inflammation over time. They will also monitor cytokine levels (TNF-alpha, IL-1beta, IL-10) and bacterial load under the gums to understand the treatment's impact. Patients will be observed to track both clinical outcomes and biochemical responses during and after the treatment period.

The trial investigates the safety and effectiveness of a medication called OCTAPLEX, a four-factor prothrombin complex concentrate, in patients experiencing acute major bleeding while on direct oral anticoagulant (DOAC) therapy with a factor Xa inhibitor. This phase 3, multicenter, prospective, randomized, double-blinded study compares two doses of OCTAPLEX, low-dose and high-dose, to assess hemostatic efficacy in this patient group. Participants will be randomly assigned in a 1:1 ratio to receive either the low-dose or high-dose OCTAPLEX. The study focuses on patients who have acute major bleeding related to their use of oral factor Xa inhibitors. Treatment administration and the comparison of dosing strategies are designed to evaluate how well OCTAPLEX controls bleeding in these patients. During the study, researchers monitor the effectiveness of the treatment by measuring hemostatic efficacy within 24 hours after starting management. Patients are closely observed for safety and treatment response. The duration of participation involves initial treatment and monitoring of bleeding control, with assessments based on clinical signs and laboratory tests related to bleeding and clotting function.